Metabolism and disposition of a gamma-aminobutyric acid type A receptor partial agonist in humans

Drug Metabolism and Disposition : the Biological Fate of Chemicals
Christopher L ShafferAaron H Burstein

Abstract

The metabolism and disposition of N-[3-fluoro-4-[2-(propylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo-1H-indole-3-carboxamide (1), a potent subtype-selective partial agonist at the gamma-aminobutyric acid type A receptor complex, were elucidated in humans following a p.o. dose of N-[3-fluoro-4-[2-(propylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo-1H-[3-(14)C]indole-3-carboxamide monomethane-sulfonate ([(14)C]1). Overall, 1 was well tolerated, with approximately twice as much radioactivity excreted in feces (64.8 +/- 13.3%) as in urine (28.4 +/- 8.8%). Across subjects, the oral clearance of 1 was composed of both renal (10%) and metabolic (< or =90%) components, with the biotransformation of 1 happening predominately via oxidative deamination to either 2-fluoro-4-[(4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carbonyl)-amino]-phenoxy acetic acid (2) or 4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid [3-fluoro-4-(2-hydroxy-ethoxy)-phenyl]-amide (3) and minimally by aliphatic hydroxylation and carbamate formation. Active renal secretion of 1 was observed as its unbound renal clearance was 6-fold greater than the glomerular filtration rate. Experiments using human hepatic in vitro systems were undertaken to better understand the e...Continue Reading

References

Dec 1, 1992·Trends in Pharmacological Sciences·W Sieghart
Mar 1, 1990·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·R W Olsen, A J Tobin
Aug 1, 1968·Biochemical Pharmacology·B Jarrott, L L Iversen
Mar 1, 1981·Clinical Pharmacology and Therapeutics·R A HamiltonB J Kline
Mar 1, 1995·Psychopharmacology·J H Woods, G Winger
Jul 1, 1993·Pharmaceutical Research·B Davies, T Morris
Dec 26, 2001·The Journal of Pharmacology and Experimental Therapeutics·H MöhlerU Rudolph
Feb 14, 2002·The Journal of Clinical Psychiatry·Robin A EmsleyDan J Stein
Dec 24, 2002·Depression and Anxiety·Hans-Ulrich Wittchen
Jan 28, 2004·Annual Review of Pharmacology and Toxicology·Wooin Lee, Richard B Kim
Jun 14, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Roselind LiebCarlo Altamura
Jun 30, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Dennis A Smith, R Scott Obach
Aug 6, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Christopher L ShafferShiyin Yee
Jul 20, 2006·The Journal of Clinical Psychiatry·Olga Brawman-MintzerKarl Rickels
Jan 1, 1995·Journal of Psychopharmacology·S Morton, M Lader
Jan 1, 2006·International Journal of Psychiatry in Clinical Practice·Ian Anderson

❮ Previous
Next ❯

Citations

Jan 1, 2010·Nature Reviews. Drug Discovery·Meir Bialer, H Steve White
Mar 26, 2010·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·A KamelA Sawant

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.